Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Plant extracts >  Astragaloside VI

Astragaloside VI

Basic information Safety Supplier Related

Astragaloside VI Basic information

Product Name:
Astragaloside VI
Synonyms:
  • Astragaloside VI
  • (3beta,6alpha,16beta,20R,24S)-20,24-Epoxy-3-[(2-O-beta-D-glucopyranosyl-beta-D-xylopyranosyl)oxy]-16,25-dihydroxy-9,19-cyclolanostan-6-yl beta-D-glucopyranoside
  • β-D-Glucopyranoside, (3β,6α,16β,20R,24S)-20,24-epoxy-3-[(2-O-β-D-glucopyranosyl-β-D-xylopyranosyl)oxy]-16,25-dihydroxy-9,19-cyclolanostan-6-yl
CAS:
84687-45-6
MF:
C47H78O19
MW:
947.11
Product Categories:
  • saponins
Mol File:
84687-45-6.mol
More
Less

Astragaloside VI Chemical Properties

Density 
1.46±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
Soluble in DMSO
pka
12.89±0.70(Predicted)
form 
Solid
color 
White to yellow
More
Less

Astragaloside VI Usage And Synthesis

Biological Activity

Astragaloside VI accelerates wound healing by activating the epidermal growth factor receptor/extracellular signal-regulated kinase (EGFR/ERK) signaling pathway.

in vitro

Pretreatment with Astragaloside VI (AS-VI) at 1 μM increases EGFR activation in HaCaT cells. Astragaloside VI, a major intestinal metabolite of astragalosides, exerts the strongest EGFR activation. In HaCaT cells, the positive control, EGF expectedly results in 1.5±0.03-fold increase in cell proliferation, compared to the control. Astragaloside VI at the indicated concentrations also significantly promots cell proliferation in both HaCaT and HDF cells. Astragaloside VI promotes neural stem cell proliferation and enhances neurological function recovery in transient cerebral ischemic injury via activating EGFR/MAPK signaling cascades.

in vivo

Astragaloside VI improves wound healing, compared to the control. In the simple noninfected wound model, wound healing in mice is accelerated by Astragaloside VI, where in the time required for wound closure is shortened by approximately 2-4 days , compared to that in the control group. Topical treatment with Astragaloside VI reduces the volume of pus produced, compared to the control group. Astragaloside VI treated wounds show an accelerated rate of healing, compared to the control and vaseline groups. By day 22, the Astragaloside VI -treated wounds fully close, whereas the blank and vaseline-treated wounds do not fully close until day 26. Angiogenesis is a crucial step in the formation of granulation tissue and wound healing. Astragaloside VI increases blood vessel formation in both the non -infected and infected wound models. Astragaloside VI could effectively activate EGFR/MAPK signaling cascades, promote NSCs proliferation and neurogenesis in transient cerebral ischemic br ains, and improve the repair of neurological functions in post-ischemic stroke rats.

target

EGFR

Astragaloside VISupplier

cjbscvictory Gold
Tel
13348960310 13348960310
Email
3003867561@qq.com
Shanghai Tauto Biotech Co., Ltd.
Tel
021-51320588
Email
tauto@tautobiotech.com
Shanghai Uteam Biotechnology Co., Ltd.
Tel
021-36031160 13311776681
Email
3338195766@QQ.com
Shanghai Biological Technology Development Co., Ltd.
Tel
021-69955236-807 13918189704
Email
chinaruji@chinaruji.com
Chengdu Push Bio-Technology Co., Ltd.
Tel
028-85370565-229 18080489829
Email
3004654993@qq.com